Cardiac CT Given Strong Recommendation as Front-line Imaging of Chest Pain, but the American Society of Nuclear Cardiology (ASNC) did not support the guidelines.
By Dave Fornell, DAIC Editor
October 29, 2021
First International Chest Pain Diagnosis Guidelines Released
October 29, 2021 — A new guideline for the evaluation and diagnosis of chest pain was released this week that provides…
Read More
Implicity provides a remote cardiac monitoring and research platform used by Independent Diagnostic Testing Facilities and medical centers to deliver high-quality care for patients with connected cardiac devices. On this platform, Implicity aggregates, normalizes and standardizes data from any implantable cardiac device across all manufacturers.
By Arnaud Rosier, M.D.
October 28, 2021
Addressing Physician Concerns About Missing CIED Patient Data
With 1.2 to 1.4 million new electrophysiology (EP) devices being prescribed to patients around the world each year,…
Read More
BioCardia's CardiAMP cell therapy uses a patient’s own (autologous) bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure to potentially stimulate the body’s natural healing response. The therapy incorporates a pre-procedural screening assay to identify those patients who are likely responders to the therapy, a first for a cardiac cell therapy. 
October 28, 2021
BioCardia Announces First Patient Treated in CardiAMP Cell Therapy Trial for Chronic Myocardial Ischemia
October 28, 2021 – The first patient has been treated in a new trial using stem cell therapy to treat chronic…
Read More
The CathVision's novel EP recording technology and amplifier ECGenius used artificial intelligence (AI) confirms if pulmonary vein isolation (PVI) is complete to reduce need for repeat EP ablations procedures.
October 28, 2021
CathVision Announces First Patient Enrollments in PVISION Multicenter Clinical Study
October 28, 2021 — CathVision, a medical technology company developing electrophysiology (EP) solutions in EP recording…
Read More
Cardiovascular Ultrasound Analytics Aids Re-accreditation Process 
October 27, 2021
The Benefits of Data Analytics in Clinical Reporting
Accurate reporting is essential to producing the reliable analytics needed to meet lab accreditation standards. This is…
Read More
October 27, 2021
FDA Revises Impulse Dynamics Optimizer Smart Device Labeling Opening it to More Patients
October 27, 2021 — Impulse Dynamics announced the U.S. Food and Drug Administration approved a modification of labeling…
Read More
October 27, 2021
Leadless CRT Can Deliver Left Bundle Branch Area Pacing for Cardiac Resynchronization
October 27, 2021 ​​— EBR Systems Inc., developer of the world’s first wireless cardiac pacing system for heart failure…
Read More
QuickClot already has an FDA-cleared product for use for vascular access hemostasis management in cath lab procedures. The hemostatic technology consists of a non-woven material impregnated with kaolin, an inorganic mineral. When kaolin contacts blood it activates Factor XII, which accelerates the body’s natural clotting cascade.
October 27, 2021
Teleflex Completes Enrollment in IDE Study of QuickClot in Cardiac Surgery
October 27, 2021 — Teleflex Inc. announced the completion of patient enrollment in a clinical study evaluating the…
Read More
By Dave Fornell, DAIC Editor
October 21, 2021
Advances in Intravascular Ultrasound Technologies
Intravascular ultrasound (IVUS) is the workhorse intravascular imaging modality in cardiac cath labs. It is used to…
Read More
HeartFlow, Inc., a leader in revolutionizing precision heart care, announced the commencement of the REVEALPLAQUE (A pRospEctiVe, multicEnter study to AnaLyze PLAQUE using CCTA) trial to evaluate HeartFlow’s non-invasive plaque technology, an automated, deep learning-based method for identifying, characterizing and segmenting plaque in the coronary arteries
October 20, 2021
HeartFlow Announces Enrollment of First Two Patients in REVEALPLAQUE Trial
October 20, 2021 — HeartFlow Inc. announced the commencement of the REVEALPLAQUE (A pRospEctiVe, multicEnter study to …
Read More
Philips, a global leader in health technology and IVUS solutions, announced that a worldwide committee of 40 cross-specialty medical experts achieved the first-ever consensus for the appropriate use of intravascular ultrasound (IVUS) in peripheral vascular disease (PVD) interventions
October 20, 2021
First-ever Global Consensus for the Appropriate Use of IVUS in Peripheral Vascular Disease Interventions
October 20, 2021 — Philips, a global leader in health technology and intravascular ultrasound (IVUS) solutions,…
Read More
The objective of this clinical investigation has been to evaluate safety and performance outcomes of SELUTION SLR, MedAlliance’s novel sirolimus-eluting balloon, for the treatment of long tibial occlusive lesions (TASC C & D) in patients with Critical Limb Ischemia (CLI). It was presented at VIVA 2021.
October 20, 2021
18-Month Below-the-Knee Data With MedAlliance’s SELUTION SLR Presented at VIVA
October 20, 2021 — 18-month results from the PRESTIGE* Below-the-Knee (BTK) study have been presented as a late-…
Read More
the Eluvia stent exhibited superiority with a primary patency rate of 85.4% versus 76.3% with BMS (p=0.0077).1 The analysis also confirmed a significantly greater rate of sustained clinical improvement without reintervention
October 20, 2021
Boston Scientific Eluvia Drug-Eluting Vascular Stent System Exhibits Superiority Compared to Bare Metal Stents
October 20, 2021 — Boston Scientific Corporation announced positive data for the Eluvia Drug-Eluting Vascular Stent…
Read More
The CorWave LVAD uses a pulse pump rather than a rotary pump to move blood, so it more closely simulates the movement of blood in a read heart.
October 20, 2021
Innovative New Pulsatile LVAD Wins 2021 HealthTech Award
October 20, 2021 – CorWave, a French medtech company developing a next-generation heart pump, won the 2021 HealthTech…
Read More
The Biotricity Biocare Cardiac app for the Samsung Galaxy Watch4 offers mobile cardiac telemetry with real-time monitoring and transmission of ECG information. It also can interface with FDA-cleared devices, including a digital thermometer, a pulse oximeter and a blood pressure cuff.
October 15, 2021
Biotricity Launches Biocare Cardiac Application for Samsung's Galaxy Watch4 Series
October 15, 2021 — Biotricity Inc. announced the release of Biocare Cardiac, a personal, cardiac health application for…
Read More
7 areas to consider to improve STEMI heart attack care
October 15, 2021
American Heart Association Offers Approaches to Improve STEMI Heart Attack Care 
October 15, 2021 — The American Heart Association (AHA) released a new policy statement that offers policy…
Read More
he correlation between poor oral health and COVID-19 severity, as well as the correlation between oral health and delayed recovery, demonstrates a potential need to consider oral health an additional risk factor for cardiac patients who may contract COVID-19. The new sub-study, examining Egyptian cardiac patients, bring presented at ACC Middle East 2021. #COVID19 #SARSCOV2
October 15, 2021
Poor Oral Health Impacts COVID severity, Especially in Cardiac Patients
October 15, 2021 — The correlation between poor oral health and COVID-19 (SARS-CoV-2) severity, as well as the…
Read More
The InspireMD CGuard Embolic Prevention Stent System (EPS) device for the treatment of carotid artery disease (CAD) and stroke prevention has received reimbursement in France from the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDIMTS) of the French National Authority for Health (HAS).
October 15, 2021
CGuard Embolic Prevention Carotid Stent Receives French Reimbursement Approval 
October 15, 2021 — The InspireMD CGuard Embolic Prevention Stent System (EPS) device for the treatment of carotid…
Read More
Cardiac CTA derived left atrium emptying fraction (LAEF) improves predictive performance of established clinical risk scores and may be used to assess TAVR patient risk during pre-procedure workup and post-procedural surveillance. These images show LAVmax (A and B), LAVmin (C and D), and LAEF using cardiac CTA. LAEF was calculated as (LAVmax-LAVmin)/LAVmax x 100. Given LAVmax of 109 mL and LAVmin of 80 mL, the LAEF was calculated to be 27%. Image courtesy of AJR.
October 14, 2021
Cardiac CTA Parameters Predict Post-TAVR Mortality
October 14, 2021 — Cardiac computed tomography angiography (CTA) derived left atrium emptying fraction (LAEF) improves…
Read More
Draft Recommendations Suggest Not Using Aspirin for Prevention in Many Patients. Risks vs. benefits of aspirin shows risks outweigh benefits in preventing heart attacks and strokes in many patients.
By Dave Fornell, DAIC Editor
October 13, 2021
Draft Recommendations Suggest Not Using Aspirin for Prevention in Many Patients
There has been debate in recent years over balancing the risks vs. benefits of aspirin for the prevention of heart…
Read More
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now